Comparative Pharmacology
Head-to-head clinical analysis: INTRALIPID 30 versus LIPOSYN III 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTRALIPID 30 versus LIPOSYN III 30.
INTRALIPID 30% vs LIPOSYN III 30%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intralipid is a source of calories and essential fatty acids. It provides a mixture of triglycerides, primarily long-chain fatty acids, which are metabolized to generate energy and serve as substrates for lipid membrane synthesis. It also prevents essential fatty acid deficiency.
Liposyn III 30% is a lipid emulsion providing essential fatty acids (linoleic and linolenic acids) and calories for parenteral nutrition. It serves as a substrate for energy production and component of cell membranes.
Intralipid 30% is administered intravenously as a component of parenteral nutrition. The typical adult dose is 1-2 g/kg/day of fat, not to exceed 60% of total calories. The infusion rate should not exceed 0.11 g/kg/hour (equivalent to 0.37 mL/kg/hour of 30% emulsion).
Adults: 1-2 g/kg/day intravenously, not to exceed 2.5 g/kg/day. Initial rate 0.5-1 mL/min for first 30 minutes, increase to 100-125 mL/h as tolerated.
None Documented
None Documented
The elimination half-life of Intralipid 30% triglycerides is approximately 30-45 minutes under steady-state conditions in patients with normal lipid metabolism, though this may extend to several hours in critically ill patients or those with impaired clearance. Clinically, the half-life is dose- and infusion-rate-dependent; for continuous infusion, clearance rates are typically 0.1-0.3 g/kg/h, with complete clearance of infused lipids within 4-6 hours after cessation of infusion in healthy adults.
The terminal elimination half-life of the triglyceride component is approximately 30 minutes (range 20-40 minutes) in patients with normal lipid metabolism. In critically ill patients or those with impaired clearance, half-life may be prolonged.
Intralipid 30% is a fat emulsion containing soybean oil, egg lecithin, and glycerin, providing essential fatty acids and triglycerides. The lipid particles are metabolized similarly to endogenous chylomicrons, primarily cleared from the bloodstream by lipoprotein lipase in peripheral tissues, releasing free fatty acids which are then utilized or stored. Less than 10% of the administered dose is excreted unchanged in urine; the majority of the lipid components are oxidized to CO2 and water or incorporated into body stores. Biliary/fecal excretion is negligible for the intact emulsion but metabolites may be excreted in bile or feces in small amounts.
Liposyn III 30% is a fat emulsion; its components are metabolized like endogenous triglycerides. Clearance involves hydrolysis by lipoprotein lipase, releasing free fatty acids which are oxidized or stored. Less than 1% is excreted unchanged in urine; a small fraction is excreted in bile/feces. No significant renal or biliary elimination of intact emulsion.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion